首页> 外文期刊>Evidence-based complementary and alternative medicine: eCAM >Based on Network Pharmacology and Molecular Docking to Explore the Underlying Mechanism of Huangqi Gegen Decoction for Treating Diabetic Nephropathy
【24h】

Based on Network Pharmacology and Molecular Docking to Explore the Underlying Mechanism of Huangqi Gegen Decoction for Treating Diabetic Nephropathy

机译:基于网络药理学和分子对接,探讨黄芪玻术治疗糖尿病肾病的潜在机制

获取原文
           

摘要

Background . Huangqi Gegen decoction (HGD), a Chinese herb formula, has been widely used to treat diabetic nephropathy in China, while the pharmacological mechanisms are still unclear. Therefore, the present study aims to explore the underlying mechanism of HGD for treating diabetic nephropathy (DN). Materials and Methods . Traditional Chinese Medicine Systems Pharmacology Database (TCMSP), UniProt, and SwissTargetPrediction databases were used to search the active ingredients and potential targets of HGD. In addition, multiple disease-related databases were used to collect DN-related targets. Common targets of the protein-protein interaction (PPI) network were established using the STRING database. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed using the DAVID database. At last, AutoDockVina was used to conduct molecular docking verification for the core components and targets. Results . A total of 27 active ingredients and 354 putative identified target genes were screened from HGD, of which 99 overlapped with the targets of DN and were considered potential therapeutic targets. Further analysis showed that the HGD activity of quercetin, formononetin, kaempferol, isorhamnetin, and beta-sitosterol ingredients is possible through VEGFA, IL6, TNF, AKT1, and TP53 targets involved in TNF, toll-like receptors, and MAPK-related pathways, which have anti-inflammatory, antiapoptosis, antioxidation, and autophagy effects, relieve renal fibrosis and renal cortex injury, and improve renal function, thus delaying the development of DN. The molecular docking results showed that quercetin, formononetin, kaempferol, isorhamnetin, beta-sitosterol had a good binding activity with VEGFA, IL6, TNF, AKT1, and TP53. Conclusion . This study demonstrated that HGD might take part in the treatment of DN through multicomponent, multitarget, and multichannel combined action.
机译:背景 。黄芪·甲王汤(HGD)是中国草药公式,已被广泛用于治疗中国的糖尿病肾病,而药理学机制仍不清楚。因此,本研究旨在探讨HGD治疗糖尿病肾病(DN)的潜在机制。材料和方法 。中药系统药理数据库(TCMSP),UNIPROT和SWISStargetPrediction数据库用于搜索有效成分和HGD的潜在目标。此外,使用多种疾病相关数据库来收集与DN相关的目标。使用字符串数据库建立蛋白质 - 蛋白质相互作用(PPI)网络的常见目标。使用DAVID数据库进行基因本体(GO)和京都基因组(KEGG)途径浓缩分析。最后,Autodockvina用于对核心组件和靶标进行分子对接验证。结果 。共有27种的活性成分和354个推定的识别出的目标基因从HGD筛选,其中99重叠DN的目标和被认为是潜在的治疗靶标。进一步的分析表明,通过VEGFA,IL6,TNF,AKT1和参与TNF,Toll样受体和MAPK相关途径的VEGFA,IL6,TNF,AKT1和TP53靶,可以通过VEGFA,IL6,TNF,AKT1和与MAPK相关途径的TP53靶来进行槲皮素,甲酰胺素,Kaempferol,Isorhamnetin和β-谷甾醇成分的HGD活性。其具有抗炎,抗痘病,抗氧化和自噬作用,缓解肾纤维化和肾皮质损伤,提高肾功能,从而延缓DN的发展。分子对接结果表明,槲皮素,甲酰胺素,Kaempferol,Isorhamnetin,Beta-sitosterol,具有VEGFA,IL6,TNF,AKT1和TP53的良好结合活性。结论 。本研究表明,HGD可能参与DN通过多组分,多元数和多通道组合行动的治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号